Nandini Piramal
Non-Executive Director and Chairperson, Piramal Enterprises and Piramal PharmaAbout
Nandini Piramal joined her family business in 2003. Seven years later, her father Ajay Piramal orchestrated one of the largest generic business deals globally, selling the domestic formulations business to Abbott in 2010 for $3.72 billion. From the remnant pharma businesses—contract development and manufacturing organisation (CDMO), complex hospital generics, and Indian consumer healthcare—Piramal was entrusted to lead consumer healthcare, besides responsibilities in HR, IT and strategy at the group level. From just three brands and sales of about ₹100 crore in 2008, she grew it to 25-plus brands and sales of about ₹1,000 crore in 2024. She took charge as chairperson of Piramal Pharma Ltd (PPL) following a group restructuring and its subsequent listing in October 2022. PPL had revenues of ₹8,171 crore in FY24. Piramal reckons the demerger of Piramal Pharma and listing, and PE fund Carlyle investing ₹3,523 crore in 2020 as key turning points. Now she has set a tougher target. “We want to double revenues and become a $2-billion-plus life-saving health and wellness company with 25% Ebitda margin by FY30 and aspire to be amongst the Top 10 companies in our addressable markets,” she says.
